Orlistat Therapy for Obesity Linked to Fewer Major Adverse Cardiovascular Events

Orlistat Therapy for Obesity is a revolutionary therapy. People with obesity using orlistat for weight loss may benefit from lower rates of overall major cardiovascular events, new-onset heart failure, renal failure, and mortality.

Because diet and lifestyle measures can have variable and limited effects on the initial management of obesity and bariatric surgery remains an invasive and expensive option, pharmacologic weight loss agents provide another weight-loss alternative for individuals with obesity.

Orlistat, a lipase inhibitor, is 1 of 4 agents approved by the US Food and Drug Administration and the only drug licensed for use in the UK. However, although previous studies have successfully measured the effect of orlistat for weight loss, its long-term effects on cardiovascular events are unknown.

The primary finding of the studies is an association between orlistat therapy and lower long-term rates of major adverse cardiovascular events; indicating that, in line with the fact that orlistat helps control weight and improve cardiovascular risk factors, it may also be associated with a sustained improvement in cardiovascular event rates,” the authors noted. (Orlistat Therapy for Obesity Linked).

You are currently viewing Orlistat Therapy for Obesity Linked to Fewer Major Adverse Cardiovascular Events

Ali Achira MD

Dr. Ali Achira Dr. Ali Achira, MD is an endocrinologist in Dearborn and in Taylor, Michigan. He is currently licensed to practice medicine in Michigan. He is affiliated with DMC Harper University Hospital. He is board certified in Internal Medicine. Board certified in Endocrinology & Diabetes, and board certified in Obesity medicine. He manages Diabetes, Thyroid, osteoporosis, Obesity and other endocrinology disorders.